|
Jul 29
|
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
|
|
Jul 28
|
Non-Invasive Prenatal Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Eurofins Scientific, F. Hoffmann-La Roche, Invitae, Illumina, Natera, Centogene, and Qiagen
|
|
Jul 24
|
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
|
|
Jul 21
|
Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates
|
|
Jul 14
|
Liberty All-Star® Growth Fund, Inc. June 2025 Monthly Update
|
|
Jul 14
|
Natera, Inc. (NTRA): A Bull Case Theory
|
|
Jul 11
|
3 Stocks Estimated To Be Undervalued By Up To 27.5% Offering Investment Opportunities
|
|
Jul 1
|
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
|
|
Jun 30
|
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
|
|
Jun 24
|
Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target
|
|
Jun 23
|
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
|
|
Jun 20
|
3 Reasons We Love Natera (NTRA)
|
|
Jun 19
|
High Growth US Tech Stocks To Watch In June 2025
|
|
Jun 10
|
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
|
|
May 27
|
3 Mid-Cap Stocks Worth Your Attention
|
|
May 22
|
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
|
|
May 21
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
May 21
|
3 Stocks That May Be Trading Below Their Estimated Value
|
|
Apr 17
|
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
|
|
Apr 16
|
3 Top Stocks Estimated To Trade At Up To 48.4% Below Intrinsic Value
|